Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

6.48
-0.0700-1.07%
Post-market: 6.12-0.3600-5.56%18:38 EDT
Volume:515.60K
Turnover:3.36M
Market Cap:354.92M
PE:-2.25
High:6.98
Open:6.62
Low:6.41
Close:6.55
52wk High:33.68
52wk Low:5.85
Shares:54.77M
Float Shares:46.68M
Volume Ratio:1.00
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8758
EPS(LYR):-2.6636
ROE:-46.05%
ROA:-30.28%
PB:1.31
PE(LYR):-2.43

Loading ...

Top Executive Makes Strategic Move With Upstream Bio Stock

TIPRANKS
·
Jun 18

Upstream Bio presents new responder analyses from VIBRANT trial of verekitug

TIPRANKS
·
Jun 15

Upstream Bio says Phase 2 VIBRANT trial shows verekitug improves nasal polyp score in about 80% of CRSwNP patients

Reuters
·
Jun 14

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in Crswnp in Significant Majority of Participants Treated With Verekitug in the Phase 2 Vibrant Trial at Eaaci 2026

THOMSON REUTERS
·
Jun 14

Upstream Bio Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $8 From $35

THOMSON REUTERS
·
Jun 12

Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor

TIPRANKS
·
Jun 11

Upstream Bio shareholders elect Fleming, Ratcliffe as Class II directors

Reuters
·
Jun 11

Upstream Bio to Showcase Additional Efficacy Data From the Phase 2 Vibrant Trial of Verekitug in Crswnp in Oral Session at Eaaci 2026

THOMSON REUTERS
·
Jun 08

Upstream Bio Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 03

Upstream Bio CEO to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 03

Upstream Bio initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Jun 03

Upstream Bio, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Jun 03

Analysts’ Top Healthcare Picks: Upstream Bio, Inc. (UPB), Plus Therapeutics (PSTV)

TIPRANKS
·
May 19

Upstream Bio presents data from Phase 2 VIBRANT trial of verekitug

TIPRANKS
·
May 18

Upstream Bio says Phase 2 trial shows verekitug improves asthma control in CRSwNP patients

Reuters
·
May 18

Upstream Bio Presents New Data From Phase 2 Vibrant Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants With Crswnp and Comorbid Asthma at the ATS 2026 International Conference

THOMSON REUTERS
·
May 18

LifeSci Capital Reaffirms Their Buy Rating on Upstream Bio, Inc. (UPB)

TIPRANKS
·
May 16

Upstream Bio releases corporate deck on verekitug Phase 3 plans for severe asthma, CRSwNP

Reuters
·
May 14

Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB)

TIPRANKS
·
May 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bolt Biotherapeutics (BOLT) and Upstream Bio, Inc. (UPB)

TIPRANKS
·
May 14